BRIEF-Immunovaccine says positive interim phase 1 data for DPX-RSV

Wed Jul 6, 2016 7:07am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 6 (Reuters) - Immunovaccine Inc

* Immunovaccine announces positive interim phase 1 data for Depovax-based respiratory syncytial virus vaccine candidate

* Safety analysis indicates that DPX-RSV was well tolerated among all study participants, with no serious adverse events recorded

* Analysis provides rationale to continue clinical testing of DPX-RSV in future human trials

* Immunovaccine announces positive interim phase 1 data for Depovax-based respiratory syncytial virus vaccine candidate Source text for Eikon: Further company coverage: